
Rein Therapeutics raises $57.5M in stock offering to fund Phase 2 trial for lung fibrosis drug.
Rein Therapeutics completed a $57.5 million underwritten public offering by selling 57.5 million shares at $1.00 each, including the full exercise of an over-allotment option. The proceeds will fund the Phase 2 clinical trial of their drug LTI-03 for...

